Burke TF - Search Results

1

The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines.

Hamdouchi C, Keyser H, Collins E, Jaramillo C, De Diego JE, Spencer CD, Dempsey JA, Anderson BD, Leggett T, Stamm NB, Schultz RM, Watkins SA, Cocke K, Lemke S, Burke TF, Beckmann RP, Dixon JT, Gurganus TM, Rankl NB, Houck KA, Zhang F, Vieth M, Espinosa J, Timm DE, Campbell RM, Patel BK, Brooks HB. Hamdouchi C, et al. Among authors: burke tf. Mol Cancer Ther. 2004 Jan;3(1):1-9. Mol Cancer Ther. 2004. PMID: 14749470

2

The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.

Yadav V, Burke TF, Huber L, Van Horn RD, Zhang Y, Buchanan SG, Chan EM, Starling JJ, Beckmann RP, Peng SB. Yadav V, et al. Among authors: burke tf. Mol Cancer Ther. 2014 Oct;13(10):2253-63. doi: 10.1158/1535-7163.MCT-14-0257. Epub 2014 Aug 13. Mol Cancer Ther. 2014. PMID: 25122067

3

Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase.

Yang H, Burke T, Dempsey J, Diaz B, Collins E, Toth J, Beckmann R, Ye X. Yang H, et al. FEBS Lett. 2005 Jun 20;579(16):3385-91. doi: 10.1016/j.febslet.2005.04.080. FEBS Lett. 2005. PMID: 15922328 Free article.

4

Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.

Tate SC, Cai S, Ajamie RT, Burke T, Beckmann RP, Chan EM, De Dios A, Wishart GN, Gelbert LM, Cronier DM. Tate SC, et al. Clin Cancer Res. 2014 Jul 15;20(14):3763-74. doi: 10.1158/1078-0432.CCR-13-2846. Epub 2014 May 21. Clin Cancer Res. 2014. PMID: 24850847

5

Identification of a BRCA1-associated kinase with potential biological relevance.

Burke TF, Cocke KS, Lemke SJ, Angleton E, Becker GW, Beckmann RP. Burke TF, et al. Oncogene. 1998 Feb 26;16(8):1031-40. doi: 10.1038/sj.onc.1201623. Oncogene. 1998. PMID: 9519877

6

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

Tate SC, Burke TF, Hartman D, Kulanthaivel P, Beckmann RP, Cronier DM. Tate SC, et al. Among authors: burke tf. Br J Cancer. 2016 Mar 15;114(6):669-79. doi: 10.1038/bjc.2016.40. Br J Cancer. 2016. PMID: 26978007 Free PMC article.

7

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.

Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB. Chen SH, et al. Among authors: burke tf. Oncogene. 2018 Feb 8;37(6):821-832. doi: 10.1038/onc.2017.384. Epub 2017 Oct 23. Oncogene. 2018. PMID: 29059158

8

SPOT: an improved differential screening protocol that allows the detection of marginally induced mRNAs.

Lemke SJ, Burke T, Boder GB, Moore RE. Lemke SJ, et al. Biotechniques. 1993 Mar;14(3):415-9. Biotechniques. 1993. PMID: 8457347

9

LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.

Barnard D, Diaz HB, Burke T, Donoho G, Beckmann R, Jones B, Barda D, King C, Marshall M. Barnard D, et al. Invest New Drugs. 2016 Feb;34(1):49-60. doi: 10.1007/s10637-015-0310-y. Epub 2015 Nov 27. Invest New Drugs. 2016. PMID: 26612134

10

Medicinal chemistry of difluoropurines.

Andis SL, Bewley JR, Boder GB, Burke T, Dudley DE, Eichelberger LE, Grossman CS, Grindey GB, Hertel LW, Jordan CL, et al. Andis SL, et al. Semin Oncol. 1995 Aug;22(4 Suppl 11):54-60. Semin Oncol. 1995. PMID: 7481846

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters